Transient hyperinsulinism in neonates
Anna V. Bolmasova,
Maria A. Melikyan,
Natalya A. Krylova,
Oleg V. Ionov,
Irina I. Ryumina,
Ekaterina L. Bockeria,
Natalya A. Pekareva,
Anna V. Degtyareva https://doi.org/10.14341/probl12572
Abstract
Congenital hyperinsulinusm is rare disease characterized high secretion of insulin by pancreatic beta cells leading to the development of hypoglycemia. Persistent and transient forms of hyperinsulinism are distinguished. Transient hyperinsulinism are the most common cause of severe hypoglycemia in newborns. The etiology of this disease is not known. There are risk factors for the development of transient hyperinsulinism: asphyxia at birth, prematurity, maternal diabetes, low or large weight by gestation. Hypoglycemia with hyperinsulinism is severe. Therefore, early diagnosis and therapy especially during the neonatal period, are necessary.
The article describes 3 clinical cases of transient hyperinsulinism in children with different gestational age and concomitant pathology. All children recevied insulinostatic therapy with diazoxide with a positive effect: euglycemia without glucose requirement . In all children, therapy was completed subsequently. At the time of publication of the article, the physical and psychomotor development of children is normal.
About the Authors
Anna V. Bolmasova
Kulakov Federal Rеseаrch Center for Obstetrics, Gynecology and Perinatology; Endocrinology research Centre
Russian Federation
Russian Federation
MD, PhD; ORCID: orcid.org/0000-0003-3127-5974, eLibrary SPIN: 7843-1604
4, Oparin street, Moscow
Maria A. Melikyan
Kulakov Federal Rеseаrch Center for Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
MD, PhD; ORCID: 0000-0002-1491-2460; eLibrary SPIN: 4184-4383
Moscow
Natalya A. Krylova
Kulakov Federal Rеseаrch Center for Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
MD; ORCID: 0000-0002-3788-0887; eLibrary SPIN: 6289-2376
Moscow
Oleg V. Ionov
Kulakov Federal Rеseаrch Center for Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
MD, PhD; ORCID: 0000-0002-4153-133X; eLibrary SPIN: 3492-6281
Moscow
Irina I. Ryumina
Kulakov Federal Rеseаrch Center for Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
MD, PhD prof; ORCID: 0000-0003-1831-887X; eLibrary SPIN: 1054-8996
Moscow
Ekaterina L. Bockeria
Kulakov Federal Rеseаrch Center for Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
MD, PhD prof; ORCID: 0000-0002-8898-961; eLibrary SPIN: 7367-6290
Moscow
Natalya A. Pekareva
Kulakov Federal Rеseаrch Center for Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
MD, PhD; ORCID: 0000-0002-6931-9672, eLibrary SPIN: 5304-2544
Moscow
Anna V. Degtyareva
Kulakov Federal Rеseаrch Center for Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
MD, PhD prof; ORCID: 0000-0003-0822-751X, eLibrary SPIN: 2361-9978
Moscow
References
1. Меликян М.А. Врожденный гиперинсулинизм: молекулярная основа, клинические особенности и персонализированное лечение: Автореф. дис. ... докт. мед. наук. — М., 2019. — 42 с. Доступно по: https://www.endocrincentr.ru/sites/default/files/specialists/science/dissertation/aut_melikyan.pdf. Ссылка активна на 15.07.2020.
2. Thornton PS, Wanner LA, Steinkrauss L, et al. Clinical features and insulin regulation in infants with a syndrome of prolonged neonatal hyperinsulinism. J Pediatr. 2006;148(2):207–212. doi: 10.1016/j.jpeds.2005.10.002.
3. Collins JE, Leonard JV. Hyperinsulinism in asphyxiated and small-fordates infants with hypoglycaemia. Lancet. 1984;2 (8398):311–313. doi: 10.1016/s0140-6736(84)92685-0.
4. Wanner LA, Steinkrauss L, Simmons RA, Stanley CA. Clinical features and insulin regulation in infants with a syndrome of prolonged neonatal hyperinsulinism. J Pediatr. 2006;148(2):207−212. doi: 10.1016/j.jpeds.2005.10.002.
5. Меликян М.А. Федеральные клинические рекомендации (протоколы) по ведению детей и подростков с врожденным гиперинсулинизмом // Проблемы эндокринологии. — 2014. Т.60. — №2. — С. 31−41. doi: 10.14341/probl201460231-41.
6. Aynsley-Green A, Hussain K, Hall J, et al. Practical management of hyperinsulinism in infancy. Arch Dis Child Fetal Neonatal Ed. 2000;82(2):F98−F107. doi: 10.1136/fn.82.2.f98.
7. Timlin MR, Black AB, Delaney HM, et al. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. Pediatr Cardiol. 2017;38(6):1247–1250. doi: 10.1007/s00246-017-1652-3.
8. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about a serious lung condition in infants and newborns treated with Proglycem (diazoxide) [cited 2015 July 16]. Available from: https://www.fda.gov/drugs/drug-safetyand-availability/fda-drug-safety-communication-fda-warns-aboutserious-lung-condition-infants-and-newborns-treated.
9. Herrera A, Vajravelu ME, Givler S, et al. Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide. J Clin Endocrinol Metab. 2018;103(12):4365–4372. doi: 10.1210/jc.2018-01613.
10. Avatapalle HB, Banerjee I, Shah S, et al. Abnormal neurodevelopmental outcomes are common in children with transient congenital hyperinsulinism. Front Endocrinol (Lausanne). 2013;4:60. doi: 10.3389/fendo.2013.00060.
11. Mizumoto H, Uchio H, Yamashita S, Hata D. Transient neonatal hyperinsulinism with adaptation disorders: a report of three cases. J Pediatr Endocr Met. 2015;28(3-4):337–340. doi: 10.1515/jpem-2014-0106.
12. Hoe FM, Thornton PS, Wanner LA, et al. Clinical features and insulin regulation in infants with a syndrome of prolonged neonatal hyperinsulinism. J Pediatr. 2006;148(2):207−212. doi: 10.1016/j.jpeds.2005.10.002.
13. Semenza GL. Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatr Res. 2001;49(5):614−617. doi: 10.1203/00006450-200105000-00002.
14. Mathupala SP, Rempel A, Pederson PL. Glucose catabolism in cancer cells: Identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem. 2001;276(46):43407−43412. doi: 10.1074/jbc.M108181200.
15. Arya VB, Flanagan SE, Kumaran A, et al. Clinical and molecular characterisation of hyperinsulinaemic hypoglycaemia in infants born small-for-gestational age. Arch Dis Child Fetal Neonatal Ed. 2013;98(4):F356−F358. doi: 10.1136/archdischild-2012-302880.
16. Hussain K, Hindmarsh P, Aynsley-Green A: Neonates with symptomatic hyperinsulinemic hypoglycemia generate inappropriately low serum cortisol counterregulatory hormonal responses. J Clin Endocrinol Metab. 2003;88(9):4342−4347. doi: 10.1210/jc.2003-030135.
17. Balachandran B, Mukhopadhyay K, Sachdeva N, et al. Randomised controlled trial of diazoxide for small for gestational age neonates with hyperinsulinaemic hypoglycaemia provided early hypoglycaemic control without adverse effects. Acta Paediatr. 2018;107(6):990−995. doi: 10.1111/apa.14252.
18. Davidov A, Elkon-Tamir E, Haham A, et al. Higher C-peptide levels and glucose requirements may identify neonates with transient hyperinsulinism hypoglycemia who will benefit from diazoxide treatment. Eur J Pediatr. 2020;179(4):597−602. doi: 10.1007/s00431-019-03544-z.
19. Yildizdas D, Erdem S, Küçükosmanoğlu O, et al. Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Adv Ther. 2008;25(5):515. doi: 10.1007/s12325-008-0049-3.
20. Timlin MR, Black AB, Delaney HM, et al. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. Pediatr Cardiol. 2017;38(6):1247−1250. doi: 10.1007/s00246-017-1652-3.
21. Le Dune MA. Response to glucagon in small-for-dates hypoglycaemic and non-hypoglycaemic newborn infants. Arch Dis Child. 1972;47(255):754−759. doi: 10.1136/adc.47.255.754.
22. Meissner T, Brune W, Mayatepak E. Persistent hyperinsulinaemic hypoglycaemic of infancy: therapy, clinical outcome and mutational analysis. Eur J Pediatr. 1997;156(10):754–757. doi: 10.1007/s004310050706.
23. Muukkonen L, Männistö J, Jääskeläinen J, et al. The effect of hypoglycaemia on neurocognitive outcome in children and adolescents with transient or persistent congenital hyperinsulinism. Dev Med Child Neurol. 2019;61(4):451−457. doi: 10.1111/dmcn.14039.
Supplementary files
Review
For citations:
Bolmasova A.V., Melikyan M.A., Krylova N.A., Ionov O.V., Ryumina I.I., Bockeria E.L., Pekareva N.A., Degtyareva A.V. Transient hyperinsulinism in neonates. Problems of Endocrinology. 2020;66(4):61-67. (In Russ.) https://doi.org/10.14341/probl12572
Views:
2685
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
